Literature DB >> 12390555

Pharmacological thromboembolic prophylaxis in a medical ward: room for improvement.

Drahomir Aujesky1, Emmanuèle Guignard, André Pannatier, Jacques Cornuz.   

Abstract

To evaluate the adequacy of pharmacological thromboembolic prevention in the medical ward of a university hospital, we performed a retrospective study in 227 consecutive inpatients. The presence of risk factors, and type, length, and dose of pharmacological prevention were documented by chart review. Only 22% of the 153 risk patients received adequate prevention, whereas 38% of the patients at low risk were given pharmacological prophylaxis. The high prevalence of over- and undertreatment is an indicator of less than optimal care. Quality of care interventions, such as the development of local guidelines, might improve the appropriateness of pharmacological thromboembolic prophylaxis in medical inpatients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390555      PMCID: PMC1495117          DOI: 10.1046/j.1525-1497.2002.10903.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  18 in total

Review 1.  Prevention of venous thromboembolism.

Authors:  W H Geerts; J A Heit; G P Clagett; G F Pineo; C W Colwell; F A Anderson; H B Wheeler
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

Review 2.  Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.

Authors: 
Journal:  BMJ       Date:  1992-09-05

3.  Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?

Authors:  D A Sandler; J F Martin
Journal:  J R Soc Med       Date:  1989-04       Impact factor: 5.344

4.  Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.

Authors:  P Mismetti; S Laporte-Simitsidis; B Tardy; M Cucherat; A Buchmüller; D Juillard-Delsart; H Decousus
Journal:  Thromb Haemost       Date:  2000-01       Impact factor: 5.249

5.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.

Authors:  M M Samama; A T Cohen; J Y Darmon; L Desjardins; A Eldor; C Janbon; A Leizorovicz; H Nguyen; C G Olsson; A G Turpie; N Weisslinger
Journal:  N Engl J Med       Date:  1999-09-09       Impact factor: 91.245

6.  High risk of the critically ill for venous thromboembolism.

Authors:  J F Cade
Journal:  Crit Care Med       Date:  1982-07       Impact factor: 7.598

7.  Fatal pulmonary emboli in hospitalized patients. An autopsy study.

Authors:  I Rubinstein; D Murray; V Hoffstein
Journal:  Arch Intern Med       Date:  1988-06

8.  Prevention of deep vein thrombosis in medical patients by low-dose heparin.

Authors:  J J Belch; G D Lowe; A G Ward; C D Forbes; C R Prentice
Journal:  Scott Med J       Date:  1981-04       Impact factor: 0.729

9.  Physician practices in the prevention of venous thromboembolism.

Authors:  F A Anderson; H B Wheeler; R J Goldberg; D W Hosmer; A Forcier; N A Patwardhan
Journal:  Ann Intern Med       Date:  1991-10-15       Impact factor: 25.391

10.  Pulmonary embolism as a cause of death. The changing mortality in hospitalized patients.

Authors:  S E Dismuke; E H Wagner
Journal:  JAMA       Date:  1986-04-18       Impact factor: 56.272

View more
  3 in total

Review 1.  Management of venous thromboembolism in the elderly.

Authors:  Alex C Spyropoulos; Geno Merli
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  Agreement of four competing guidelines on prevention of venous thromboembolism and comparison with observed physician practices: a cross-sectional study of 1,032 medical inpatients.

Authors:  José Labarère; Jean-Luc Bosson; Jean-François Bergmann; Nathalie Thilly
Journal:  J Gen Intern Med       Date:  2004-08       Impact factor: 5.128

3.  Risk of venous thromboembolism and benefits of prophylaxis use in hospitalized medically ill US patients up to 180 days post-hospital discharge.

Authors:  Li Wang; Nishan Sengupta; Onur Baser
Journal:  Thromb J       Date:  2011-10-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.